ivonescimab + nab-paclitaxel

Ivonescimab + nab-paclitaxel is a combination therapy being investigated for various cancers, particularly triple-negative breast cancer (TNBC). **Components:** - **Ivonescimab (SMT112/AK112)**: A novel bispecific antibody that simultaneously targets PD-1 and VEGF. It features a tetravalent structure with four binding sites that enable higher avidity in the tumor microenvironment, with over 18-fold increased binding affinity to PD-1 in the presence of VEGF and over 4-times increased binding affinity to VEGF in the presence of PD-1. - **Nab-paclitaxel (Abraxane)**: An albumin-bound formulation of paclitaxel that stabilizes microtubules in cancer cells, preventing them from disassembling and inhibiting cell division. The combination leverages both immunotherapy (PD-1 blockade), anti-angiogenesis (VEGF blockade), and cytotoxic effects to target cancer cells through multiple mechanisms.

Brand names

Abraxane + ivonescimab